Table 4. Impact of VMMC on HIV infections averted in base case, by country, 2011–2015 and 2011–2025.

Country	Time Period	Additional VMMCs (Millions)	HIV Infections Averted (Millions)	HIV Infections Averted (Percentage)	VMMC per HIV Infection Averted
Botswana	2011–2015	0.35	0.01	12	36
	2011–2025	0.49	0.06	28	8
Lesotho	2011–2015	0.38	0.01	12	28
	2011–2025	0.54	0.11	37	5
Malawi	2011–2015	2.10	0.03	11	66
	2011–2025	3.04	0.24	28	13
Mozambique	2011–2015	1.06	0.03	5	38
	2011–2025	1.53	0.22	13	7
Namibia	2011–2015	0.33	0.00	9	109
	2011–2025	0.48	0.02	25	26
Nyanza Province, Kenya	2011–2015	0.38	0.01	6	36
	2011–2025	0.57	0.07	16	8
Rwanda	2011–2015	1.75	0.01	10	239
	2011–2025	2.53	0.06	29	44
South Africa	2011–2015	4.33	0.14	7	30
	2011–2025	5.94	1.08	20	5
Swaziland	2011–2015	0.18	0.01	12	25
	2011–2025	0.27	0.06	34	5
Tanzania	2011–2015	1.38	0.02	3	56
	2011–2025	1.98	0.20	9	10
Uganda	2011–2015	4.25	0.05	10	91
	2011–2025	6.35	0.34	25	19
Zambia	2011–2015	1.95	0.04	12	43
	2011–2025	2.87	0.34	30	8
Zimbabwe	2011–2015	1.91	0.06	13	31
	2011–2025	2.17	0.57	42	4
Total	2011–2015	20.34	0.43	8	47
	2011–2025	28.76	3.36	22	9

Table 4 presents the additional VMMCs and the impact of VMMC on HIV infections averted for 2011–2015 and 2011–2025 for the base case scenario. HIV infections averted are not discounted.